Thank you for your patience while we retrieve your images.
Imbruvica®

Imbruvica®

Malignant B-Cell showing dis-regulated protein signaling pathways to inside of cell, highlighting the B-Cell receptor, Toll-like receptor, and the CXCR4/5 Chemokine receptor, with free-floating cytokines and chemokines. Imbruvica® is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the Bruton’s tyrosine kinase (BTK), part of a crucial signaling pathway in certain cancers, thereby inhibiting the B-cell receptor pathway that is often aberrantly active in B-cell leukemias and lymphomas. Exhibition display, 8 feet tall x 22 feet wide, for Janssen Biotech, Inc.